Gentamicin and carbenicillin, used alone or in combination, are now among the most widely used antibiotics for the treatment of serious, hospital-acquired, gram-negative bacillary infections. Although the activity by weight of gentamicin against Enterobacteriaceae and Pseudomonas aeruginosa is comparable to other aminoglycosides, several problems have been associated with its clinical use. First, the mean peak blood level obtained with gentamicin at commonly recommended dosages (1.5 mg/kg) is about 4 pg/ml, whereas the trough level is often less than 1 Ag/ml. This peak level may barely exceed the minimal inhibitory concentration (MIC) of many gram-negative isolates and it is likely that larger doses will be associated with greater toxicity. Second, clinically significant gentamicin-resistant organisms are being reported with increasing frequency (14, 19) . Carbenicillin is the only clinically available penicillin with activity against P. aeruginosa, Serratia, and indole-positive Proteus sp. However, a number of reports have documented the rapid development of carbenicillin resistance during therapy (12, 13) . For these reasons, new antimicrobial agents of the aminoglycoside or semisynthetic penicillin classes continue to be investigated for their in vitro activity against those gram-negative bacilli which are difficult to treat. In this report, we have compared the activity of gentamicin to amikacin (BB-K8) and aminodeoxybutirosin (A-butirosin) and carbenicillin to a new semisynthetic penicillin, BL-P1654, against approximately 60 clinical isolates of Proteus mirabilis, indole-positive Proteus, P. aeruginosa, and Serratia marcescens.
The in vitro testing was performed in accord with the methods recommended by the International Collaborative Study (ICS) on antimicrobial testing sponsored by the World Health Organization (8) . Standard reference strains from the Pasteur Institute Collection (among ghose reviewed by the ICS) were used so that the results of this study can be compared with data from other laboratories using standard methods and these reference strains.
( Plastic petri dishes containing serial twofold dilutions of antibiotics in agar were prepared within 48 h of use. An inoculum of approximately 1 x 10' organisms diluted from an overnight broth culture was used. The organisms were delivered to dry agar surfaces using the inoculum replicating device of Steers et al. (20) . The Ca2+ and Mg2+ concentration of the media was determined by an atomic absorption spectrophotometer and expressed in milligram percent. Broth MIC was determined by inoculating 1 x 10 organism from an overnight culture into MHB and recording the lowest concentration of antibiotic which yielded a clear tube at 24 h. All clear tubes were subcultured onto blood agar and the minimal bactericidal concentration (MBC) was that concentration which yielded less than 5 colonies at 24 h.
Standard reference strains Escherichia coli 53.153 and P. aeruginosa 58.38 obtained from the collection of the Pasteur Institute were kindly provided by Yves Chabbert. Each plate was inoculated with 30 clinical isolates and both reference strains.
Criteria for susceptibility. Isolates were considered susceptible if they were inhibited at or below the peak serum level achieved during administration of drug to patients or normal volunteers. For gentamicin, this was 4 ug/ml at a dose of 1.5 mg/kg; for amikacin and aminodeoxybutirosin, 16 ,g/ml at a dose of 7.5 mg/kg; and for carbenicillin and BL-P1654, 128 jg/ml for a dose of 4 g and 1 g, respectively. The inhibitory index refers to the ratio between the mean peak serum levels given above and the MIC for at least M of each species tested (22) .
RESULTS
Each isolate was tested a minimum of three times by the agar dilution method to determine the MIC. The two standard reference strains were tested on each plate as an internal control. Reference strains were thus rechecked more than 20 times each, and showed no greater than a one dilution variation.
Susceptibility of clinical isolates to three aminoglycosides. The in vitro susceptibility of clinical isolates of four different species are represented in Fig. 1-4 .
The concentration of gentamicin to inhibit 50% of the isolates of P. mirabilis was 1.5 jig/ml; for amikacin, 4 ug/ml; and for aminodeoxybutirosin, 8 xg/ml ( The activity of gentamicin, amikacin, and aminodeoxybutirosin against 57 clinical isolates of Pseudomonas aeruginosa. therapeutic range. Inhibition of 50% of isolates of P. aeruginosa by gentamicin, amikacin, and aminodeoxybutirosin was achieved at 4, 16, and 32 ug/ml, respectively (Fig. 2) . With these agar dilution tests, the curve representing cumulative percent inhibition of P. aeruginosa by gentamicin and amikacin showed its greatest increment at one dilution above the mean peak serum levels for each drug. Fifty percent of indole-positive Proteus sp. was susceptible to gentamicin at 1 gg/ml, amikacin at 2 ,ug/ml, and aminodeoxybutirosin at 4 jig/ml (Fig. 3) . At the mean peak serum levels, 81% of isolates were inhibited by gentamicin, 95% were inhibited by amikacin, and 96% were inhibited by VOL. 7, 1975 on aminodeoxybutirosin. Fifty percent of the Serratia strains were susceptible to 0.5, 1.5, and 2.5 Mg/ml of gentamicin, amikacin, and aminodeoxybutirosin, respectively. At mean peak serum levels, gentamicin inhibited 77% of these strains, amikacin 74% of strains, and aminodeoxybutirosin 75% of strains.
Susceptibility of clinical isolates to two penicillins. At 8 Mg/ml for BL-P1654 and between 16 to 32 ,g/ml for carbenicillin, approximately 50% of P. aeruginosa strains were inhibited. At 128 Mug/ml (peak serum level), 95% of strains were inhibited by both agents (Fig. 5) . Fifty percent of S. marcenscens was inhibited by 16 mg/ml of BL-P1654 and carbenicillin, and at 128 ,ug/ml the MIC for 90% of isolates was exceeded by both drugs. Both carbenicillin and BL-P1654 were quite active against P. mirabilis, as greater than 90% of isolates were inhibited by either agents at only 4 Mg/ml (Fig. 7) . In contrast, the activity of the two agents against indole-positive Proteus sp. differed markedly (Fig. 7) . Pseudomonas, the results were comparable and did not differ by more than a single dilution. For P. aeruginosa, the aminoglycosides were least active on 1.5% agar, and most active in MHB probably reflecting the differences in the concentration of Ca2+ + Mg24 in the media (Table   4) . DISCUSSION The spectrum of these aminoglycoside antibiotics was similar but on a weight basis gentamicin was clearly the most active, amikacin intermediate, and aminodeoxybutirosin least active. This order of activity against the four species of bacteria tested was in agreement with previous reports (22, 23) . To factor for the differences in pharmacokinetics between amikacin and gentamicin (6), inhibitory indices were calculated to relate potency by weight with achievable serum levels (22) . Using this approach, amikacin appears to offer no theoretical advantage over gentamicin, except against isolates of S. marcescens. It should be borne in mind, however, that highly gentamicin-resistant strains are often susceptible to amikacin, whereas the few strains studied which are resistant to amikacin are also gentamicin resistant (5, 18) . Amikacin is effective against, bacterial strains resistant to other aminoglycQsides because it is a poor substrate for enzymes that inactivate aminoglycosides by phosphorylation, or adenylation (2, 18) . Comparative clinical studies will be required to determine whether one of these agents has any therapeutic advantages over the other.
Aminodeoxybutirosin is a chemical modification of butirosin, the latter being obtained from fermentation filtrates of Bacillus circulans. Butirosin and aminodeoxybutirosin resemble amikacin in activity and pharmacokinetics (7, 11 (18) . The effect of divalent cation concentration in culture media on the activity of gentamicin against Pseudomonas has been extensively investigated and is confirmed in this report (9, 10, 15) . The interaction of Ca2+ and Mg2+ with the bacterium probably occurs at the cell wall and this increases the structural stability of the cell wall resulting in increased resistance to aminoglycoside antibiotics (24) . Based upon broth dilution susceptibility in this study and average peak serum levels, greater than 95% of the Pseudomonas would be susceptible to gentamicin and amikacin. An important question is whether the rather high degree of resistance encountered in this study compared to earlier reports from this and other laboratories can be reconciled on the basis of technical differences and/or the use of media with varying divalent cation content. Since one dilution variation of MICs in relation to peak serum levels dramati-cally changes the prevalence of resistant strains and since as much as eightfold differences are observed between broth and agar tests, these factors probably explain the variations that have been encountered. The interpretation of this data with regard to the physiologic state of the host is even more important. Since the effect of Mg2+ is greater than that of Ca2+, and since the concentration of Mg2+ in MHA is closer to that in human serum, the results of tests using MHA may be more clinically relevant than those using MHB.
The two penicillins compared in this study have a comparable spectrum. Bodey and Stewart (4) and Price et al. (16) have shown BL-P1654 to be more active in vitro than carbenicillin against Pseudomonas and Serratia, but Adler and Finland could demonstrate no significant difference against Pseudomonas (1). Our data agree with the latter study. The reason for the difference in results is probably related to the marked effect of culture media on BL-P1654 (17, 21) . The weakly basic BL-P1654 has up to a 40-fold reduction in activity on MHA as compared to nutrient broth. Carbenicillin, which is acidic, does not show this variation. MHA is a more reliable indicator of the relative in vivo potency of BL-P1654 and carbenicillin than nutrient agar (17) . The 
